Poseida Therapeutics (PSTX) Appoints Rafael G. Amado to its Board

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Rafael G. Amado, M.D., to its Board of Directors, effective today.

"I am thrilled to welcome Rafael to the Board of Directors of Poseida. His deep expertise and experience in oncology, immunotherapy and both allogeneic CAR-T and TCR-T adoptive cell therapy for the treatment of cancers make him an ideal addition to complement the strengths of our Board," said Mark Gergen, Chief Executive Officer of Poseida. "With his strong track record in both pharma and biotech leadership he is positioned to provide strategic insight as we continue pursuing our mission to redefine cell and gene therapies in cancer, genetic diseases and beyond."

"I am honored to join the Board at Poseida, as it advances a new class of cell and gene therapies with tremendous promise," said Dr. Amado. "I believe the Company's genetic engineering technologies have the potential to reshape the landscape of off-the-shelf cell therapies and offer new treatment options for patients fighting cancer. I look forward to working closely with Poseida as the Company continues to develop its exciting pipeline in oncology and rare genetic diseases."

Dr. Amado currently serves as President, Head of Global Oncology Research and Development at Zai Lab, a public biopharmaceutical company. Prior to Zai Lab, Dr. Amado served as Executive Vice President, Head of Research and Development and Chief Medical Officer from September 2019 to December 2022 at Allogene Therapeutics, Inc. and President of Research and Development from August 2018 to August 2019 and Chief Medical Officer from March 2015 to August 2018 at Adaptimmune, LLC. Prior to Adaptimmune, Dr. Amado held various roles of increasing responsibility at GlaxoSmithKline, most recently as Senior Vice President and Global Head of Oncology Research and Development, and at Amgen Inc., where he was last Executive Director of Clinical Research and Global Development in Therapeutic Oncology. Prior to joining Amgen, he held academic roles at the University of California, Los Angeles (UCLA) in the Department of Medicine, Division of Hematology / Oncology. Dr. Amado received an M.D. from the University of Seville School of Medicine in Seville, Spain and completed his internship and residency in Internal Medicine at the Michael Reese Hospital and Medical Center and a fellowship in Hematology / Oncology at UCLA.

You May Also Be Interested In

• J.M. Smucker names Jeff Varcoe as SVP of Science and Technical
• Vortex Metals hires advisory firm, appoints two former U.S. ambassadors
• SuperCom wins third Texas electronic monitoring contract